Rituximab in relapsed/refractory antineutrophil cytoplasmic antibody associated vasculitis: A single-center prospective observational study

Rituximab in relapsed/refractory antineutrophil cytoplasmic antibody associated vasculitis: A single-center prospective observational study

Background: Induction with cyclophosphamide (CYC) and glucocorticoids in antineutrophil cytoplasmic antibody-associated vasculitis (AAV) has a relapse of 30%–50%. Studies show that rituximab (RTX) is superior to CYC in refractory/relapsed AAV. We prospectively analyzed efficacy and safety of RTX in...

Disgrifiad llawn

Manylion Llyfryddiaeth
Prif Awduron: Ekbote Gayatri, Tanna Dhaval, Negalur Natasha, Bindroo Muzaffar, Raval Dhiren, Sharma Lucky, Rajiva Gupta
Fformat: Erthygl
Iaith:English
Cyhoeddwyd: SAGE Publishing 2019-01-01
Cyfres:Indian Journal of Rheumatology
Pynciau:
Antineutrophil cytoplasmic antibody-associated vasculitis
granulomatosis with polyangiitis
rituximab
Mynediad Ar-lein:http://www.indianjrheumatol.com/article.asp?issn=0973-3698;year=2019;volume=14;issue=1;spage=12;epage=16;aulast=Gayatri

Rhyngrwyd

http://www.indianjrheumatol.com/article.asp?issn=0973-3698;year=2019;volume=14;issue=1;spage=12;epage=16;aulast=Gayatri

Eitemau Tebyg